Prevention of breast cancer: The case for studying inhibition of IGF-1 actions

Annals of Oncology

Volumn 22, Issue SUPPL. 1, 2011, Pages

  Smith, J ^a   Axelrod, D ^a   Singh, B ^a   Kleinberg, D ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; IGF 1; Mammary development; Pasireotide; Raloxifene; SOM230; Tamoxifen

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GLUCOSE; PASIREOTIDE; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MECHANISM; EXERCISE; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; ONCOGENE; PILOT STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; QT PROLONGATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 79551650729     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq666     Document Type: Article

References (10)

1. Rockhill B, Spiegelman D, Byrne C et al. Validation of the Gail, et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358-366.
2. Muggia FM, Greenspan EM. Workshop on chemoprevention of breast cancer (Meeting report). Cancer Res 1984; 44: 3151-3154.
3. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
4. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
5. Ruan W, Newman CB, Kleinberg DL. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992; 89: 10872-10876.
6. Ruan W, Monaco ME, Kleinberg DL. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-1 action. Endocrinology 2005; 146: 1170-1178.
7. Ruan W, Fahlbusch F, Clemmons DR et al. SOM230 inhibits IGF-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol 2006; 20: 426-436.
8. Yee D, Chavez JB, Ruan WF, Kleinberg DL. Inhibition of normal mammary gland development and breast cancer growth by IGFBP1. Proceedings of the American Society for Clinical Oncology Annual Meeting. Clin Pharmacol 2000: 209a (Abstr 813).
9. Novartis. Clinical Development SOM 230 Pasireotide s.c and pasireotide LAR Investigator's Brochure. Novartis Investigator's Brochure Edition 9, 2010.
10. Kim HJ, Litzenburger BC, Cui X et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-tomesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007; 27: 3165-3175.